Neil J Wimmer1, Eric A Secemsky1, Laura Mauri1, Matthew T Roe1, Paramita Saha-Chaudhuri1, David Dai1, James M McCabe1, Frederic S Resnic1, Hitinder S Gurm1, Robert W Yeh2. 1. From the Division of Cardiology, Department of Medicine, Christiana Care Health System, Newark, DE (N.J.W.); Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston (E.A.S.); Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (L.M.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (M.T.R., D.D.); Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, CA (P.S.-C.); Division of Cardiology, Department of Medicine, University of Washington, Seattle (J.M.M.); Division of Cardiology, Department of Medicine, Lahey Clinic, Burlington, MA (F.S.R.); Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor (H.S.G.); and Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y.). 2. From the Division of Cardiology, Department of Medicine, Christiana Care Health System, Newark, DE (N.J.W.); Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston (E.A.S.); Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (L.M.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (M.T.R., D.D.); Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, CA (P.S.-C.); Division of Cardiology, Department of Medicine, University of Washington, Seattle (J.M.M.); Division of Cardiology, Department of Medicine, Lahey Clinic, Burlington, MA (F.S.R.); Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor (H.S.G.); and Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y.). ryeh@bidmc.harvard.edu.
Abstract
BACKGROUND: Bleeding is associated with poor outcomes after percutaneous coronary intervention (PCI). Although arterial closure devices (ACDs) are widely used in clinical practice, whether they are effective in reducing bleeding complications during transfemoral PCI is uncertain. The objective of this study was to evaluate the effectiveness of ACDs for the prevention of vascular access site complications in patients undergoing transfemoral PCI using an instrumental variable approach. METHODS AND RESULTS: We performed a retrospective analysis of the CathPCI Registry from 2009 to 2013 at 1470 sites across the United States. Variation in the proportion of ACDs used by each individual physician operator was used as an instrumental variable to address potential confounding. A 2-stage instrumental variable analysis was used as the primary approach. The main outcome measure was vascular access site complications, and nonaccess site bleeding was used as a falsification end point (negative control) to evaluate for potential confounding. A total of 1 053 155 ACDs were used during 2 056 585 PCIs during the study period. The vascular access site complication rate was 1.5%. In the instrumental variable analysis, the use of ACDs was associated with a 0.40% absolute risk reduction in vascular access site complications (95% confidence interval, 0.31-0.42; number needed to treat=250). Absolute differences in nonaccess site bleeding were negligible (risk difference, 0.04%; 95% confidence interval, 0.01-0.07), suggesting acceptable control of confounding in the comparison. CONCLUSIONS: ACDs are associated with a modest reduction in major bleeding after PCI. The number needed to treat with ACDs to prevent 1 major bleeding event is high.
BACKGROUND:Bleeding is associated with poor outcomes after percutaneous coronary intervention (PCI). Although arterial closure devices (ACDs) are widely used in clinical practice, whether they are effective in reducing bleeding complications during transfemoral PCI is uncertain. The objective of this study was to evaluate the effectiveness of ACDs for the prevention of vascular access site complications in patients undergoing transfemoral PCI using an instrumental variable approach. METHODS AND RESULTS: We performed a retrospective analysis of the CathPCI Registry from 2009 to 2013 at 1470 sites across the United States. Variation in the proportion of ACDs used by each individual physician operator was used as an instrumental variable to address potential confounding. A 2-stage instrumental variable analysis was used as the primary approach. The main outcome measure was vascular access site complications, and nonaccess site bleeding was used as a falsification end point (negative control) to evaluate for potential confounding. A total of 1 053 155 ACDs were used during 2 056 585 PCIs during the study period. The vascular access site complication rate was 1.5%. In the instrumental variable analysis, the use of ACDs was associated with a 0.40% absolute risk reduction in vascular access site complications (95% confidence interval, 0.31-0.42; number needed to treat=250). Absolute differences in nonaccess site bleeding were negligible (risk difference, 0.04%; 95% confidence interval, 0.01-0.07), suggesting acceptable control of confounding in the comparison. CONCLUSIONS: ACDs are associated with a modest reduction in major bleeding after PCI. The number needed to treat with ACDs to prevent 1 major bleeding event is high.
Authors: R G Brindis; S Fitzgerald; H V Anderson; R E Shaw; W S Weintraub; J F Williams Journal: J Am Coll Cardiol Date: 2001-06-15 Impact factor: 24.094
Authors: Robert J Applegate; Matthew T Sacrinty; Michael A Kutcher; Frederic R Kahl; Sanjay K Gandhi; Renato M Santos; William C Little Journal: JACC Cardiovasc Interv Date: 2008-06 Impact factor: 11.195
Authors: Jeremy A Rassen; Sebastian Schneeweiss; Robert J Glynn; Murray A Mittleman; M Alan Brookhart Journal: Am J Epidemiol Date: 2008-11-25 Impact factor: 4.897
Authors: W S Weintraub; C R McKay; R N Riner; S G Ellis; P L Frommer; D B Carmichael; K E Hammermeister; M N Effros; J E Bost; D P Bodycombe Journal: J Am Coll Cardiol Date: 1997-02 Impact factor: 24.094
Authors: Steven V Manoukian; Frederick Feit; Roxana Mehran; Michele D Voeltz; Ramin Ebrahimi; Martial Hamon; George D Dangas; A Michael Lincoff; Harvey D White; Jeffrey W Moses; Spencer B King; E Magnus Ohman; Gregg W Stone Journal: J Am Coll Cardiol Date: 2007-03-09 Impact factor: 24.094
Authors: Jeremy A Rassen; M Alan Brookhart; Robert J Glynn; Murray A Mittleman; Sebastian Schneeweiss Journal: J Clin Epidemiol Date: 2009-04-05 Impact factor: 6.437
Authors: Duane S Pinto; Gregg W Stone; Chunxue Shi; Elizabeth S Dunn; Matthew R Reynolds; Meghan York; Joshua Walczak; Ronna H Berezin; Roxana Mehran; Brent T McLaurin; David A Cox; E Magnus Ohman; A Michael Lincoff; David J Cohen Journal: J Am Coll Cardiol Date: 2008-11-25 Impact factor: 24.094
Authors: Bina Ahmed; Winthrop D Piper; David Malenka; Peter VerLee; John Robb; Thomas Ryan; Michael Herne; William Phillips; Harold L Dauerman Journal: Circ Cardiovasc Interv Date: 2009-09-01 Impact factor: 6.546
Authors: Eric A Secemsky; Enrico G Ferro; Sunil V Rao; Ajay Kirtane; Hector Tamez; Pearl Zakroysky; Daniel Wojdyla; Steven M Bradley; David J Cohen; Robert W Yeh Journal: JAMA Cardiol Date: 2019-02-01 Impact factor: 14.676
Authors: Neel M Butala; Mabel Chung; Eric A Secemsky; Pratik Manandhar; Guillaume Marquis-Gravel; Andrzej S Kosinski; Sreekanth Vemulapalli; Robert W Yeh; David J Cohen Journal: JACC Cardiovasc Interv Date: 2020-06-08 Impact factor: 11.195
Authors: Eric A Secemsky; Neel M Butala; Uri Kartoun; Sadiqa Mahmood; Jason H Wasfy; Kevin F Kennedy; Stanley Y Shaw; Robert W Yeh Journal: J Am Heart Assoc Date: 2016-10-17 Impact factor: 5.501
Authors: Andrew Prouse; Elise Gunzburger; Fan Yang; Justin Morrison; Javier A Valle; Ehrin J Armstrong; Stephen W Waldo Journal: J Am Heart Assoc Date: 2020-02-16 Impact factor: 5.501